Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Adv Healthc Mater. 2020 Sep 23;9(21):e2000880. doi: 10.1002/adhm.202000880

Figure 5.

Figure 5.

Drug response of MDA-MB-231 to doxorubicin under different conditions in L-TumorChip. (A) Drug response kinetics of MDA-MB-231 cell in the presence of HMVEC treated with or without doxorubicin and the effect of presence of HMVEC endothelium barrier in the device. Caspase-3 activity in the bottom chamber was normalized to time 0 fluorescence intensity value in each condition. The drug was given at day 2 post-seeding. Results are represented as average ± S.D. (n = 3). Significance between treated and non-treated groups (both cultured with HMVEC) at the endpoint (48h) was determined using Student t-test (*, p < 0.05) (B) Caspase-3 activity of MDA-MB-231 at 48h post-treatment. Drug response kinetics of MDA-MB-231 under different tumor microenvironment conditions. Results are represented as average ± S.D. (n = 3).